Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Step by step instructions to Involve Compact disc Rates for Magnanimous Giving - 2Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
- 3A definitive Burger Confrontation: Which One Rules?
- 4Canada's Serene Lakeside Mountain Village Is A Breathtaking Oasis For Outdoor Adventure
- 5Instructions to Clean and Really focus on Your Lab Precious stone
- Dramatic Dominance d: A Survey of \Feelings in front of an audience\ Theater Play
- The most effective method to Pick the Best Wellbeing Highlights for Seniors in SUVs
- What Yogurt Types Do You Know
- Shrewd Home Gadgets to Save Energy
- Allow Innovative Progressions To have a Massive Effect
- Transcript: Scott Gottlieb on "Face the Nation with Margaret Brennan," Dec. 7, 2025
- The most effective method to Involve Handshakes for Compromise and Compromise
- Weather forecast, Turkana style: A goat's intestines tell it all
- Key Little Things That Advantage Old People
